{"database": "lobbying", "table": "lobbying_activities", "is_view": false, "human_description_en": "where filing_period = \"third_quarter\", filing_year = 2021 and issue_code = \"PHA\" sorted by filing_year descending", "rows": [[2675418, "e2c5bbea-923b-4487-819a-2c82c131aea4", "Q3", "LUNGREN LOPINA LLC", 401103314, "AMPAC FINE CHEMICALS", 2021, "third_quarter", "PHA", "Fair treatment for US based pharmaceutical ingredients", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-09-27T16:38:07.957000-04:00"], [2675966, "248c2449-bae5-4452-a830-60ecdd75b586", "3T", "RED+BLUE STRATEGIES", 400693064, "PEW CHARITABLE TRUSTS", 2021, "third_quarter", "PHA", "PL 117-2 - The American Rescue Plan Act Implementation - Issues related to the increased substance use disorder crisis in America, the need for a more robust pipeline for antibiotics to protect the nation, a more coherent HIT system to ensure robust public data and other related public health issues. \n\nS. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. \n\nS. 963 - Mainstreaming Addiction Treatment Act (The MAT Act) - Supporting access to MAT to help avoid opioid-related deaths in the country. \n\nS. 2076 - The Pioneering Antimicrobial Subscriptions to End Surging Resistance Act ( PASTEUR Act) - Issues related to improving the antibiotic pipeline to address antimicrobial resistance.\n\nIssues related to ensuring clear information regarding the safety of supplements. \n\nIssues related to dealing with antimicrobial resistance among the US population.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 1, "2021-10-03T11:20:41.550000-04:00"], [2676066, "c75f644f-7937-43e1-a672-d9019562331a", "Q3", "AMERICAN COLLEGE OF CLINICAL PHARMACY", 57258, "AMERICAN COLLEGE OF CLINICAL PHARMACY", 2021, "third_quarter", "PHA", "Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE", null, 144981, 0, 0, "2021-10-04T10:02:17.787000-04:00"], [2676594, "df650e9b-fe60-4ac0-8694-40da89e5e04e", "Q3", "VICKI J HICKS", 401106146, "A2 STRATEGIES, LLC OBO PHIBRO ANIMAL HEALTH CORPORATION", 2021, "third_quarter", "PHA", "Animal health issues.", "SENATE", null, null, 0, 0, "2021-10-06T11:03:30.170000-04:00"], [2676663, "94e8a2c0-2e88-4089-90c7-7e2b0dc42679", "Q3", "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 26672, "NATIONAL ASSOCIATION OF CHAIN DRUG STORES", 2021, "third_quarter", "PHA", "Interfaced with the White House, Operation Warp Speed; HHS Secretary and team, and CDC to drive COVID testing & vaccinations across the nation.\n\nH.R. 1002 Debarment Enforcement of Bad Actor Registrants Act\n\nH.R. 1899 Ensuring Compliance Against Drug Diversion Act", "Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 370000, 0, 0, "2021-10-06T12:09:49.377000-04:00"], [2676850, "33a22331-4872-45eb-aa5f-4e16f2516a50", "Q3", "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 401103605, "PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION", 2021, "third_quarter", "PHA", "COVID-19 vaccine & therapeutic production, and pandemic protection.\nPharmaceutical supply chain and domestic manufacturing", "HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2021-10-07T09:38:56.130000-04:00"], [2676997, "3625bf38-b6f0-40b5-b6b7-00866b8bb143", "Q3", "REPUBLIC CONSULTING, LLC", 401016871, "IQVIA", 2021, "third_quarter", "PHA", "Monitored Health Data Policy.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-07T13:59:53.117000-04:00"], [2677367, "3b531f7c-1c4b-42b0-9c74-e757ddf53f93", "Q3", "STONINGTON GLOBAL", 401105189, "SORRENTO THERAPEUTICS, INC.", 2021, "third_quarter", "PHA", "Regulatory approvals and funding for pharmaceutical products and devices", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 150000, null, 0, 0, "2021-10-08T13:55:06.893000-04:00"], [2677393, "446c48c7-1ad8-4d76-ab1e-3e7238e5202e", "3T", "STONINGTON GLOBAL", 401105189, "NOSTRUM PHARMACEUTICALS LLC", 2021, "third_quarter", "PHA", "Issues affecting generic pharmaceutical manufacturers", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 1, "2021-10-08T14:17:17.110000-04:00"], [2677485, "5c581cfe-d2f7-4842-a6b8-8ba85e4d93fa", "Q3", "INDEPENDENT PHARMACY COOPERATIVE", 313098, "INDEPENDENT PHARMACY COOPERATIVE", 2021, "third_quarter", "PHA", "IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. \nIPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 \nIPC supports Pharmacists as Immunizers\nIPC supports 340B Program and contract pharmacies\nIPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion.\nIPC supports MCO Medicaid reform and elimination of spread pricing", "Centers For Medicare and Medicaid Services (CMS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 30000, 0, 0, "2021-10-08T17:13:53.780000-04:00"], [2677611, "3ea2815e-9ec5-48b8-97ca-ee782d9676e9", "Q3", "PENN AVENUE PARTNERS", 400918672, "ALKERMES, INC.", 2021, "third_quarter", "PHA", "Regulatory and legislative issues impacting Alkermes.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-10T11:57:32.233000-04:00"], [2677664, "4e81ea50-cec0-4e31-8754-937dc7699d4f", "Q3", "PENN AVENUE PARTNERS", 400918672, "UNITEDHEALTH GROUP, INC.", 2021, "third_quarter", "PHA", "Pharmacy benefit related issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 90000, null, 0, 0, "2021-10-10T12:41:48.527000-04:00"], [2677717, "4bb74057-da1d-4629-a972-9f7fcb913240", "Q3", "RED+BLUE STRATEGIES", 400693064, "PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA)", 2021, "third_quarter", "PHA", "Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule.\n\nH.R. 3684 - INVEST in America Act - Support for delay of the Trump Administration's Rebate rule\n\nPL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance.", "Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2021-10-10T17:45:02.870000-04:00"], [2677742, "8858a006-cb0f-4089-a008-ae3d743d72ce", "Q3", "RED+BLUE STRATEGIES", 400693064, "COHERUS BIOSCIENCES", 2021, "third_quarter", "PHA", "Build Back Better Act - Issues related to supporting the growth of biosimilars in America to provide competition and tools to lower the cost of prescription medications\n\nWork to advance policies that support companies that fully manufacture products in America. \n\n\nS. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. \n\nIssues and policies that incent companies to increase their US footprint and adopt Made in America business practices. \n\nPolicies to help grow the biosimilars marketplace in the United States. \n\nPolicies focused on improving cancer care through access to affordable treatments.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-11T09:33:13.227000-04:00"], [2677863, "c56a41ca-ad49-477b-899f-50b09bc7c53e", "Q3", "POLSINELLI PC", 314911, "TEVA PHARMACEUTICALS USA, INC.", 2021, "third_quarter", "PHA", "Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products\nReview of Administration telehealth policies", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-10-11T14:17:55.427000-04:00"], [2678075, "003da944-73d3-413b-b724-0cf05b01ad4f", "Q3", "NATIONAL ADVOCACY CENTER OF THE SISTERS OF THE GOOD SHEPHERD", 77993, "CONFERENCE OF PROVINCIALS OF NORTH AMERICA", 2021, "third_quarter", "PHA", "Advocated to lower the cost of prescription drugs as part of the FY2022 Budget Resolution and in Build Back Better.", "Agriculture, Dept of (USDA),Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Interior, Dept of (DOI),Justice, Dept of (DOJ),SENATE,State, Dept of (DOS),Treasury, Dept of,U.S. Agency for International Development (USAID),Vice President of the U.S.,White House Office", 40000, null, 0, 0, "2021-10-11T16:17:43.907000-04:00"], [2678430, "c529c99a-2a1a-447d-a4d7-c01659f7809b", "Q3", "AMERICAN PHARMACISTS ASSOCIATION", 3071, "AMERICAN PHARMACISTS ASSOCIATION", 2021, "third_quarter", "PHA", "H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes.\nH.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes.\nH.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers.\nH.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit.", "HOUSE OF REPRESENTATIVES,SENATE", null, 35000, 0, 0, "2021-10-12T12:24:16.420000-04:00"], [2678556, "7aaf670f-2498-4d1d-a5ef-6183f6b789c5", "Q3", "PANNONE LOPES DEVEREAUX & O'GARA LLC", 401105501, "AMGEN", 2021, "third_quarter", "PHA", "Prescription drug pricing.", null, 9000, null, 0, 0, "2021-10-12T13:45:46.987000-04:00"], [2678885, "03f11e99-0518-4f0c-b231-b257d8754b06", "Q3", "MCDERMOTT+ LLC", 401103287, "ALLIANCE FOR RURAL HOSPITAL ACCESS", 2021, "third_quarter", "PHA", "Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853).", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-12T18:01:03.233000-04:00"], [2679215, "2528ad86-fe3b-4a85-8fde-6c9077a3a12c", "Q3", "ISEMAN & ASSOCIATES LLC", 401103582, "TICHENOR VENTURES, LLC", 2021, "third_quarter", "PHA", "Monitoring biotech legislation; prescription drug prices; COVID- Relief legislation; Infrastructure Legislation; FY22 Appropriations bills", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2021-10-13T12:03:07.827000-04:00"], [2679289, "794f689d-3f48-4c1d-96bf-26ab06c73e60", "Q3", "MLJ STRATEGIES", 401105126, "ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS", 2021, "third_quarter", "PHA", "Advocating on issues related to pharmaceutical appropriations", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-10-13T13:30:29.443000-04:00"], [2679296, "4d39bc6f-cc06-4c89-ba6a-5d9530d62251", "Q3", "MLJ STRATEGIES", 401105126, "ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH", 2021, "third_quarter", "PHA", "Advocate on issues related to supplement use in the military", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-10-13T13:34:31.737000-04:00"], [2679653, "c0855fd6-afe8-476c-8705-3a2b542a6da6", "Q3", "CONNECT 4 STRATEGIES, LLC", 401103720, "OREXO US, INC.", 2021, "third_quarter", "PHA", "Legislative and regulatory issues pertaining to Orexo\nImplementation of the SUPPORT act.\nAccess to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-13T19:37:17.113000-04:00"], [2680508, "bd48ed63-4c99-466a-8c28-173cface19bd", "Q3", "FOLEY & LARDNER LLP", 15042, "BLINK HEALTH LTD (A BERMUDA LIMITED COMPANY)", 2021, "third_quarter", "PHA", "Market-based solutions to drug pricing and chain pharmacy barriers to generic pharmaceutical price reduction.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-14T14:37:48.057000-04:00"], [2680625, "875b3d2f-5d28-4a21-9296-c2980e5aa947", "Q3", "FOLEY & LARDNER LLP", 15042, "ENDO USA, INC., A MALLINCKRODT-ENDO COMPANY", 2021, "third_quarter", "PHA", "FDA issues; Issues relating to prescription drug abuse; Issues relating to CDC guidance for prescribing opioids; Issues relating to removal of FDA unapproved products from the market.", "HOUSE OF REPRESENTATIVES,SENATE", 70000, null, 0, 0, "2021-10-14T15:30:18.290000-04:00"], [2680748, "3a60c080-78ae-42e9-b955-4bb454565880", "Q3", "BOLD STRATEGIES, LLC", 401104653, "MORRIS & DICKSON CO., LLC", 2021, "third_quarter", "PHA", "Prescription drug issues generally.", "HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2021-10-14T17:04:59.657000-04:00"], [2680904, "8374170c-c6e3-42cf-9e22-cc2d7e39cbfa", "Q3", "FOLEY & LARDNER LLP", 15042, "FOUNDATION CONSUMER HEALTHCARE LLC", 2021, "third_quarter", "PHA", "Legislation and regulations affecting marketing and commercialization of prescription and non-prescription drugs", "HOUSE OF REPRESENTATIVES,SENATE", 5000, null, 0, 0, "2021-10-14T21:08:52.990000-04:00"], [2680907, "25b8deaf-bdfa-433f-a9a7-8a75b09d6b20", "Q3", "ACG ADVOCACY", 2057, "WALGREEN CO.", 2021, "third_quarter", "PHA", "Drug Pricing Policy Issues.\nData privacy and DIR fee reform.\nCounterfeiting Issues.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-14T21:10:54.097000-04:00"], [2681020, "6c003377-d233-4902-8737-f21fd1db5463", "Q3", "TODD STRATEGY GROUP", 401103321, "ALKERMES, INC.", 2021, "third_quarter", "PHA", "Prescription drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-15T08:06:34.127000-04:00"], [2681059, "d728036f-f8a7-4953-9aeb-29ab21eacd48", "Q3", "TODD STRATEGY GROUP", 401103321, "ASTRAZENECA PHARMACEUTICALS LP", 2021, "third_quarter", "PHA", "Drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-15T09:25:44.177000-04:00"], [2681060, "c50e6701-37d7-4c2a-ad6d-54b0536f9543", "Q3", "TODD STRATEGY GROUP", 401103321, "BAYER CORPORATION", 2021, "third_quarter", "PHA", "Drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-15T09:28:44.743000-04:00"], [2681073, "b78f988f-2dba-400f-b0f8-36be09077ccf", "Q3", "TODD STRATEGY GROUP", 401103321, "BIOTECHNOLOGY INNOVATION ORGANIZATION", 2021, "third_quarter", "PHA", "Drug pricing and access.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 60000, null, 0, 0, "2021-10-15T09:40:48.793000-04:00"], [2681074, "c39b7c8c-1950-4fa2-ac62-beea8db62ef6", "Q3", "TODD STRATEGY GROUP", 401103321, "CAREDX, INC.", 2021, "third_quarter", "PHA", "Immunosuppressive drug coverage implementation.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES", 40000, null, 0, 0, "2021-10-15T09:41:49.363000-04:00"], [2681077, "7b37a819-003d-4a88-bdb9-56f4b4abbb70", "Q3", "NELSON MULLINS RILEY & SCARBOROUGH", 285871, "HEMOPHILIA OF GEORGIA", 2021, "third_quarter", "PHA", "340B Drug Pricing Program, Medicare, biomedical research, ACA implementation and COVID-19 response and relief legislation", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-10-15T09:46:50.440000-04:00"], [2681114, "dc811b3c-4bfc-4c46-89bb-94e5988fe2bd", "Q3", "LINCOLN PARK GROUP L.L.C.", 401104374, "CANADIAN INTERNATIONAL PHARMACY ASSOCIATION", 2021, "third_quarter", "PHA", "Support for S. 920/H.R. 2181 - A bill to amend the Federal Food, Drug, and Cosmetic Act to allow for the importation of affordable and safe drugs by wholesale distributors, pharmacies, and individuals and S. 259/H.R. 832 - Safe and Affordable Drugs from Canada Act; issues related to personal drug importation.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-15T10:11:01.400000-04:00"], [2681144, "6b5c2cb5-84dd-40de-8e48-ae7d88a7b288", "Q3", "TODD STRATEGY GROUP", 401103321, "EMD SERONO INC.", 2021, "third_quarter", "PHA", "Drug pricing policy.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-15T10:18:07.857000-04:00"], [2681164, "46cc416b-ee40-418f-82a2-6f3bb5a5a8c3", "Q3", "TODD STRATEGY GROUP", 401103321, "GENENTECH, INC.", 2021, "third_quarter", "PHA", "Prescription drug payment reform.\nSupply chain.\nStrategic National Stockpile.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-15T10:22:12.460000-04:00"], [2681205, "72212c13-2eee-43bc-a74b-9c01b66a0058", "Q3", "TODD STRATEGY GROUP", 401103321, "MERCK & CO., INC.", 2021, "third_quarter", "PHA", "Drug Pricing.\n340B Issues.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-10-15T10:35:23.847000-04:00"], [2681209, "8f8b7488-7287-43e8-a879-b7a9d2287f51", "Q3", "TODD STRATEGY GROUP", 401103321, "NOVARTIS, INC.", 2021, "third_quarter", "PHA", "Drug Pricing.\nSupply Chain.\n340B Issues.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-15T10:40:25.810000-04:00"], [2681223, "e37012ae-4da2-47ca-9f01-15f2f0bff617", "Q3", "TODD STRATEGY GROUP", 401103321, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2021, "third_quarter", "PHA", "Drug Pricing and Access.\nPharmaceutical Supply Chain.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-15T10:43:29.550000-04:00"], [2681251, "e54be645-16c7-4735-89a7-a846cbb561ec", "Q3", "UNIVERSITY OF IOWA", 49191, "UNIVERSITY OF IOWA", 2021, "third_quarter", "PHA", "Support for National Center of Excellence in Advanced and Continuous Pharmaceutical Manufacturing legislation", "Agriculture, Dept of (USDA),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE", null, 60000, 0, 0, "2021-10-15T10:46:32.843000-04:00"], [2681473, "95663fe8-3130-4491-87fb-e18632b3c30a", "Q3", "BALLARD PARTNERS", 401104288, "THE CRANEWARE GROUP (F.K.A. SENTRY DATA SYSTEMS)", 2021, "third_quarter", "PHA", "340B Drug Discount Program.", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-10-15T12:02:35.457000-04:00"], [2681485, "169df1f1-0e58-410d-bdb2-bbe86c75c22a", "Q3", "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 312496, "CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER", 2021, "third_quarter", "PHA", "340B", "Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office", null, 31485, 0, 0, "2021-10-15T12:07:40.287000-04:00"], [2681495, "3700fff0-d18a-4c7c-9d95-cbf12831bbbf", "Q3", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "GLENMARK PHARMACEUTICALS, INC., USA", 2021, "third_quarter", "PHA", "Issues related to affordability, essential medicine manufacturing and supply chain, and pricing of pharmaceuticals.  General issues related to the generic drug industry.  Issues related to H.R. 2853, the BLOCKING Act of 2021.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-15T12:10:43.697000-04:00"], [2681599, "ddfc45b6-83fa-438d-b236-fd6679a625b9", "Q3", "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 27478, "NATIONAL COMMUNITY PHARMACISTS ASSOCIATION", 2021, "third_quarter", "PHA", "S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021;\nH.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021;\nH.R. 3656, the Vaccine Access Improvement Act of 2021;\nH.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021;\nCOVID vaccine distribution;\nPharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act;\nH.R. 4390, the PROTECT 340B Act of 2021;\nS. 1574, the Long-Term Care Pharmacy Definition Act of 2021;\nProvider Relief Fund;\nImplementation of Pubic Law 113-54, the Drug Quality and Security Act;", "Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Federal Reserve System,Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Justice, Dept of (DOJ),Occupational Safety & Health Administration (OSHA),SENATE,Small Business Administration (SBA),Treasury, Dept of,White House Office", null, 420000, 0, 0, "2021-10-15T13:05:07.690000-04:00"], [2681796, "159a4999-edab-4d0e-8b1c-7d1225b030f9", "Q3", "PUBLIC CITIZEN", 32362, "PUBLIC CITIZEN", 2021, "third_quarter", "PHA", "HR3778/S 1976 (NOVID Act); Covid-19 Vaccine manufacturing and access and related funding, HR 3 (Lower Drug Costs Now Act, Senate Finance Drug price reform package, Aducanumab, Drug pricing, Insulin affordability for all Act, Medicare Negotiation and Competitive Licensing Act, We PAID Act, S. 1435-Affordable Prescriptions for Patients Act, Vaccine manufacturing and NDAA", "Consumer Product Safety Commission (CPSC),Equal Employment Opportunity Commission (EEOC),Federal Accounting Standards Advisory Board (FASAB),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE,Treasury, Dept of,White House Office", null, 80000, 0, 0, "2021-10-15T14:38:47.207000-04:00"], [2681843, "e5b0bc3a-7857-4f26-8a50-2c58f6b78da2", "Q3", "BROWN & FORTUNATO, P.C.", 401104878, "PROMPTCARE COMPANIES, INC.", 2021, "third_quarter", "PHA", "Issues related to Medicare home infusion therapy benefit and other health care issues.  Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators.", "Centers For Medicare and Medicaid Services (CMS)", 20000, null, 0, 0, "2021-10-15T14:46:55.773000-04:00"], [2682354, "9c734d76-dd36-4042-9aaa-efd8ad1447fd", "Q3", "AMERICAN VETERINARY MEDICAL ASSOCIATION", 3630, "AMERICAN VETERINARY MEDICAL ASSOCIATION", 2021, "third_quarter", "PHA", "Prescription Mandate legislation\nCompounding Guidance (GFI 256)", "Agriculture, Dept of (USDA),Education, Dept of,Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 210000, null, 0, 0, "2021-10-15T21:26:03.973000-04:00"], [2682536, "b19dc5fe-625e-4628-a695-92228b66eaea", "Q3", "BLUE CROSS AND BLUE SHIELD ASSOCIATION", 6358, "BLUE CROSS AND BLUE SHIELD ASSOCIATION", 2021, "third_quarter", "PHA", "COVID-19 Testing; COVID-19 Vaccine Strategy and Treatment; Vaccine Rollout; Rx reform; Prescription drugs; Prescription Drug Reform; \n\nH.R. 550 - Immunization Infrastructure Modernization Act of 2021\nSponsor: Rep. Annie Kuster (D-NH-02)\n\nH.R. 951 - Maternal Vaccination Act\nSponsor: Rep. Terri Sewell (D-AL-07)\n\nH.R. 2347 - Strengthening the Vaccines for Children Program Act of 2021\nSponsor: Rep. Kim Schrier (D-WA-08)\n\nH.R. 3742 - Vaccine INFO Act\nSponsor: Rep. Gus Bilirakis (R-FL-12)\n\nH.R. 3 -  Lower Drug Costs Now Act\nSponsor: Rep. Frank Pallone (D-NJ-06)\n\n\nH.R. 2355 - Opioid Prescription Verification Act of 2021\nSponsor: Rep. Rodney David (R-IL-13)", "Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),SENATE,White House Office", null, 1350000, 0, 0, "2021-10-16T05:14:43.767000-04:00"], [2682555, "a3df2660-d18e-4b67-86cf-7312571df5c8", "Q3", "MARSHALL & POPP, LLC", 401105121, "AMGEN USA INC.", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T08:51:29.393000-04:00"], [2682558, "3be130e4-ba5b-4e81-bfaa-e63b0107e3c2", "Q3", "MARSHALL & POPP, LLC", 401105121, "BUTTERFLY NETWORK, INC.", 2021, "third_quarter", "PHA", "Issues related to medical device manufacturing / insurance / technology.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-16T08:58:29.997000-04:00"], [2682574, "f83c1fac-7221-416c-b040-03f86a362f4b", "Q3", "MARSHALL & POPP, LLC", 401105121, "GENENTECH, INC.", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T09:14:34.210000-04:00"], [2682588, "36379c31-fa0e-408c-b3eb-8918f279216c", "Q3", "MARSHALL & POPP, LLC", 401105121, "PFIZER, INC.", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T09:25:38.690000-04:00"], [2682594, "91162211-0aa7-411d-b8f0-d88ee7545097", "Q3", "MARSHALL & POPP, LLC", 401105121, "PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-16T09:29:39.803000-04:00"], [2682601, "44afd58b-0f40-462b-93c8-71022e394e63", "Q3", "MARSHALL & POPP, LLC", 401105121, "SANOFI U.S. SERVICES, INC.", 2021, "third_quarter", "PHA", "Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; Budget reconciliation recommendations reported by House committees pursuant to S.Con.Res. 14.\n\nIssues related to vaccine development and distribution.\n\nIssues related to supply chains, 340B, and the COVID-19 pandemic.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T09:32:41.543000-04:00"], [2682815, "546c6f2e-c1d5-49de-8c1d-f7a6e0b042f5", "Q3", "GOVERNMENT COUNSEL, LLC", 401105070, "HEALTHCARE DISTRIBUTION ALLIANCE", 2021, "third_quarter", "PHA", "H.R. 768-Block, Report, And Suspend Suspicious Shipments Act of 2021; Policies related to ARCOS data and suspicious order record requirements; Implementation of Public Law 113-54 (DSCSA).", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-16T13:49:04.577000-04:00"], [2683160, "504e615d-c9be-44d7-b953-aa6a7638a7d3", "Q3", "CAPITOL COUNSEL LLC", 313715, "EMD SERONO, INC.", 2021, "third_quarter", "PHA", "Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-16T19:53:30.727000-04:00"], [2683263, "59786460-4ea0-4226-83f8-7eb256239856", "Q3", "FORBES-TATE", 400976792, "INDEPENDENT PHARMACY COOPERATIVE", 2021, "third_quarter", "PHA", "Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-17T11:49:08.777000-04:00"], [2683909, "d207093d-26aa-471c-a1bc-1d48d99ec587", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "AMNEAL", 2021, "third_quarter", "PHA", "Monitoring legislative and regulatory efforts related to domestic supply chains of generic drugs.\nPandemic Preparedness.\nThe Build Back Better Act, a bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.", "Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 60000, null, 0, 0, "2021-10-18T09:37:51.060000-04:00"], [2683938, "29c1dd4d-8c36-4442-8a43-0a8e22a15a94", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "ASCENSION HEALTH ALLIANCE", 2021, "third_quarter", "PHA", "340B Drug Pricing Program. \nFinancial support for providers for diagnosis and treatment related to COVID-19, coverage of COVID-19 related conditions, access to PPE and other materials and equipment related to the treatment of patients with COVID-19.\nThe Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-18T09:44:58.323000-04:00"], [2683947, "8ea90ca2-9432-4d22-b6b6-a6ca4bc75bdd", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "BLUE SHIELD OF CALIFORNIA", 2021, "third_quarter", "PHA", "Prescription drug pricing.\nThe Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-18T09:48:00.907000-04:00"], [2684159, "4094bd0e-dbac-41bb-be1e-29eea35ef496", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "THE CAMPAIGN FOR SUSTAINABLE RX PRICING", 2021, "third_quarter", "PHA", "S.1391 - Fair Accountability and Innovative Research Drug Pricing Act.\nPrescription drug pricing issues.\nPatent abuse issues.\nEnsuring Innovation Act and the Advancing Education on Biosimilars Act of 2021.\nDrug-price Transparency for Competition (DTC) Act.\nThe Build Back Better Act, A bill to provide for reconciliation pursuant to title II of the Concurrent Resolution on the Budget for Fiscal Year 2022, S. Con. Res. 14.", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 110000, null, 0, 0, "2021-10-18T10:33:53.350000-04:00"], [2684179, "5c3e7275-f994-4ffa-b0ca-d05d21a626d3", "Q3", "AARP", 1694, "AARP", 2021, "third_quarter", "PHA", "H.R. 5376 Build Back Better Act. \n\nNo bill number. Discussed prescription drugs prices and costs and Medicare.\n\nH.R. 4356,  Agriculture, Rural Development Appropriations Act, FY 2022. \n\nS. 1428, the Preserve Access to Affordable Generics and Biosimilars Act.\n\nS. 1287, the REFUND Act.", "Administration for Children & Families (ACF),Agriculture, Dept of (USDA),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Consumer Financial Protection Bureau (CFPB),Corporation for Natl & Community Service,Defense, Dept of (DOD),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Labor, Dept of (DOL),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office", null, 2980000, 0, 0, "2021-10-18T10:37:55.780000-04:00"], [2684230, "830b5b4e-ae0d-44f8-a7cb-bdf2f6fc8d95", "Q3", "MEHLMAN CONSULTING, INC.", 284950, "VIZIENT INC", 2021, "third_quarter", "PHA", "Issues related to Unapproved Drug Initiative.", "Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office", 60000, null, 0, 0, "2021-10-18T10:50:09.973000-04:00"], [2684279, "98120117-54e1-4674-9044-931ce97af690", "Q3", "WATKINS & EAGER PLLC", 401104403, "ZYNERBA PHARMACEUTICALS, INC.", 2021, "third_quarter", "PHA", "Providing services on behalf of Zynerba to the pharmaceutical industry", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2021-10-18T10:59:21.243000-04:00"], [2684283, "aa7d8769-bde2-45a3-ad63-04dfb09367d4", "Q3", "WAXMAN STRATEGIES", 401103693, "340B HEALTH", 2021, "third_quarter", "PHA", "Issues affecting the 340B drug pricing program; Appropriations for 340B program.", "HOUSE OF REPRESENTATIVES,SENATE", 45000, null, 0, 0, "2021-10-18T10:59:21.750000-04:00"], [2684659, "89c7f8ed-ccb8-495e-ace3-869d045caf65", "Q3", "BRAEBURN INC. FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 401104621, "BRAEBURN INC FORMERLY KNOWN AS BRAEBURN PHARMACEUTICALS INC", 2021, "third_quarter", "PHA", "HR 1629, S250 Fairness in Orphan Drug Exclusivity Act; Administration of controlled substances by HCPs; Storage of controlled substances", "HOUSE OF REPRESENTATIVES,SENATE,White House Office", null, 100000, 0, 0, "2021-10-18T12:03:00.890000-04:00"], [2684820, "644c826f-f452-4042-8235-dde0167ed442", "Q3", "FORBES-TATE", 400976792, "CALIFORNIA LIFE SCIENCES ASSOCIATION", 2021, "third_quarter", "PHA", "Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-18T12:26:40.670000-04:00"], [2685174, "09824afa-ff19-49f7-81f1-3f27f93e467b", "Q3", "CORNERSTONE GOVERNMENT AFFAIRS, INC.", 75557, "VYRIPHARM ENTERPRISES, INC.", 2021, "third_quarter", "PHA", "Policies and regulations associated with testing, tracing and tracking of cannabinoids.", "HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE", 30000, null, 0, 0, "2021-10-18T14:01:21.610000-04:00"], [2685301, "9adcf7df-0924-43ac-82bd-f530fc32d657", "Q3", "FORBES-TATE", 400976792, "MERCK", 2021, "third_quarter", "PHA", "Issues related to prescription drug pricing, vaccines, animal health, and maternal health.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-18T14:27:50.743000-04:00"], [2685646, "025d29dd-3015-4af5-b399-5e9fb27be353", "Q3", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "ASTRAZENECA", 2021, "third_quarter", "PHA", "Drug coverage & reimbursement\nvaccination\n\nno specific bills, Import Safety, drug development policy, drug shortages, supply chain integrity, Innovation, reimportation, transparency, 340B, pay for delay", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-10-18T14:50:48.073000-04:00"], [2685824, "f457df06-815e-4441-9e06-fc422b1667d0", "Q3", "FORBES-TATE", 400976792, "PHRMA", 2021, "third_quarter", "PHA", "Issues pertaining to prescription drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-10-18T15:09:26.693000-04:00"], [2685995, "b227d517-6264-4c06-980d-db34be734d54", "Q3", "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 29403, "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", 2021, "third_quarter", "PHA", "OTC switch process -- no bill number\n\nCures 2.0 -- no bill number\n\nS.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021\n\nH.R.4405 - Small Business FDA User Fee Adjustment Act of 2021", "Commerce, Dept of (DOC),Food & Drug Administration (FDA),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of", null, 133000, 0, 0, "2021-10-18T15:26:05.173000-04:00"], [2686418, "aeae88ed-97c3-4d77-9625-a2d2fed5ecb5", "Q3", "SUSAN B ANTHONY LIST", 400935704, "SUSAN B ANTHONY LIST", 2021, "third_quarter", "PHA", "H.R. 554, S. 78 Support and Value Moms and Babies Act; Chemical abortion", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", null, 230000, 0, 0, "2021-10-18T16:13:33.260000-04:00"], [2686512, "b0c49244-04c1-43e8-8e8f-355008fd822d", "Q3", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "BIOTECHNOLOGY INDUSTRY ORGANIZATION", 2021, "third_quarter", "PHA", "H.R. 1319, American Rescue Plan of 2021 implementation\n\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, patent settlements, break through therapies, Innovation, transparency\n\nno specific bills, Drug Safety, Prescription Drug Importation, Import Safety, supply chain integrity, biosimilars, PDUFA and associated policies, patent settlements, accelerated approval, break through therapies, compounding, user fee reauthorization, Innovation", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 80000, null, 0, 0, "2021-10-18T16:27:57.893000-04:00"], [2686744, "60ebd16e-cbe7-4ede-aa95-c10789192e5c", "Q3", "WINNING STRATEGIES WASHINGTON", 50796, "KALEO", 2021, "third_quarter", "PHA", "Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-10-18T17:06:53.627000-04:00"], [2686776, "b26d9696-4e6e-477c-abe0-6a6fc1e5cb6d", "Q3", "HANCE SCARBOROUGH", 17443, "BOEHRINGER INGELHEIM USA CORPORATION", 2021, "third_quarter", "PHA", "Provide ongoing animal health policy monitoring, assessment, and research support.  Telemedicine/telehealth legislation.", "HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-10-18T17:18:00.967000-04:00"], [2686801, "4a01986b-27c3-4cd5-a31a-e60a04a92216", "Q3", "HANCE SCARBOROUGH", 17443, "ALLIANCE FOR PHARMACY COMPOUNDING", 2021, "third_quarter", "PHA", "Issues related to the regulation of pharmacy compounding.\n\nIssues related to preserving patient access to compounded medications.\n\nFiscal Year 2022 Appropriations\n\nHR3662, the Patient Access to Urgent Use Compounded Medication Act", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-18T17:25:06.193000-04:00"], [2686810, "b9014dc0-e00a-4d03-9e69-61f96b4ce868", "Q3", "BROWNSTEIN HYATT FARBER SCHRECK, LLP", 7257, "AIPHARMA GLOBAL HOLDINGS LIMITED", 2021, "third_quarter", "PHA", "Issues related to the pharmaceutical supply chain", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,White House Office", 80000, null, 0, 0, "2021-10-18T17:28:08.097000-04:00"], [2686841, "c24ef9e9-c2cf-4fec-b079-ee00d306acef", "Q3", "HANCE SCARBOROUGH", 17443, "PHRMA", 2021, "third_quarter", "PHA", "Patent reform regarding pharmaceutical research & products.", "SENATE", 30000, null, 0, 0, "2021-10-18T17:37:14.677000-04:00"], [2686846, "24e32f99-8678-4843-8be7-9bd1fd91a211", "Q3", "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 401104060, "THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH", 2021, "third_quarter", "PHA", "General education around pharmaceuticals related to Parkinson's disease", "Centers For Medicare and Medicaid Services (CMS),Environmental Protection Agency (EPA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE", null, 52751, 0, 0, "2021-10-18T17:37:15.593000-04:00"], [2686874, "c677cea8-e9ce-4202-a7ba-17eb77b024b7", "Q3", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION)", 2021, "third_quarter", "PHA", "Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021.  Issues related to COVID-19 vaccine distribution.  Issues related to the implementation of H.R. 1319, the American Rescue Plan.  Issues related to pharmacy provider status.  Issues related to oncology medicines in H.R. 5067, the Preserving Patient Access to Home Infusion Act.", "Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE", 60000, null, 0, 0, "2021-10-18T17:50:21.420000-04:00"], [2687250, "6c204db0-76ba-4575-8365-38b582889bab", "Q3", "KNIGHT CAPITOL CONSULTANTS", 40036301, "EQUASHIELD, LLC", 2021, "third_quarter", "PHA", "Provisions affecting vial reuse being discussed in connection with drug pricing legislation (H.R. 5376, Build Back Better Act).", "Centers For Disease Control & Prevention (CDC),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-10-18T21:18:53.907000-04:00"], [2687294, "bd357551-47b2-4c50-96d2-919b0c79a27c", "Q3", "KNIGHT CAPITOL CONSULTANTS", 40036301, "REGENXBIO", 2021, "third_quarter", "PHA", "Possible legislation which may affect Food and Drug Administration review of biologic products (no specific bill)", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-18T21:43:03.370000-04:00"], [2687303, "9dcb06e3-7553-46f0-aacc-0be30e7009d3", "Q3", "WEST FRONT STRATEGIES LLC", 401103493, "WALGREEN CO.", 2021, "third_quarter", "PHA", "Issues related to COVID-19 vaccination programs;\nissues related to pharmacy, pharmacist provider status, and Medicare reimbursement.", "HOUSE OF REPRESENTATIVES,SENATE", 50000, null, 0, 0, "2021-10-18T21:55:06.483000-04:00"], [2687340, "6245f9ed-c797-4d92-ba0c-bd7b662fb8b2", "Q3", "FLYNN & ASSOCIATES, INC.", 15020, "PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION", 2021, "third_quarter", "PHA", "H.R. 3 -  Price controls for prescription drugs.\nImportation of drugs from other countries.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-18T22:32:14.263000-04:00"], [2687813, "316fa875-1e94-410b-ab2b-6c2341de1a40", "Q3", "VAN SCOYOC ASSOCIATES", 39837, "ZEBRA TECHNOLOGIES CORP.", 2021, "third_quarter", "PHA", "Temperature monitoring technology for COVID-19 vaccines, Domestic and International distribution related issues\n\nTemperature monitoring technology, generally", "HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-10-19T05:32:00.937000-04:00"], [2687882, "f77ff540-32d3-4b2b-bf38-6a930fc75da9", "Q3", "BROYDRICK & ASSOCIATES", 7268, "EXELA PHARMA SCIENCES", 2021, "third_quarter", "PHA", "Drug shortages and FDA approval, USTR acceptance.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 10000, null, 0, 0, "2021-10-19T06:35:15.933000-04:00"], [2687911, "8abcfded-18ed-48e9-82b9-4114531a7b38", "Q3", "BROYDRICK & ASSOCIATES", 7268, "TONIX PHARMACEUTICALS", 2021, "third_quarter", "PHA", "Funding new drug for PTSD and COVID 19.", "Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE", 20000, null, 0, 0, "2021-10-19T06:49:26.830000-04:00"], [2688016, "68af04a9-4366-400c-a0bb-72c5d5e29dc7", "Q3", "MASSACHUSETTS MEDICAL SOCIETY", 23975, "MASSACHUSETTS MEDICAL SOCIETY", 2021, "third_quarter", "PHA", "Issues related to prescription drug prices - no specific bill\nIssues related to vaccines - no specific bill", "Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Treasury, Dept of,Veterans Affairs, Dept of (VA),White House Office", null, 50000, 0, 0, "2021-10-19T08:34:59.760000-04:00"], [2688248, "1e0e8337-b35b-4214-b18b-08b9df1778a0", "Q3", "TARPLIN, DOWNS & YOUNG, LLC", 304736, "HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.)", 2021, "third_quarter", "PHA", "Opioid Abuse - General issues related to opioid abuse (implementation of Public Law 115-271)\nIssues related to ARCOS data and suspicious order record requirements and reporting (HR 768) \nImportation of Prescription Drugs (HR 832, HR 2181, S 259, S 920, Public Law 108-173) \nImplementation of Public Law 113-54 (DSCSA)", "Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-10-19T09:17:45.540000-04:00"], [2688451, "9ae26008-a4a1-4795-8f34-2645e9954c25", "Q3", "ELI LILLY AND COMPANY", 13392, "ELI LILLY AND COMPANY", 2021, "third_quarter", "PHA", "Hospital discounts; 340B program", "Commerce, Dept of (DOC),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Office of Management & Budget (OMB),SENATE,State, Dept of (DOS),U.S. Trade Representative (USTR)", null, 1320000, 0, 0, "2021-10-19T09:41:40.167000-04:00"], [2688550, "80a30d2a-42af-444f-afb5-73e4f624442a", "Q3", "CRISPR THERAPEUTICS, INC.", 401105184, "CRISPR THERAPEUTICS, INC.", 2021, "third_quarter", "PHA", "Coverage & reimbursement for Cell and Gene Therapies", "Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE", null, 50000, 0, 0, "2021-10-19T09:51:07.977000-04:00"], [2688769, "f345b90a-2cd0-48fc-9d86-6278b01e676f", "Q3", "M.J. SIMON & COMPANY, LLC", 40026223, "NOBELPHARMA AMERICA", 2021, "third_quarter", "PHA", "FDA inspections", "HOUSE OF REPRESENTATIVES,SENATE", null, null, 0, 0, "2021-10-19T10:09:52.907000-04:00"], [2688890, "8b3deb0e-803e-4166-81a7-c80287090924", "Q3", "TWENTY-FIRST CENTURY GROUP, INC.", 38687, "CARDINAL HEALTH, INC.", 2021, "third_quarter", "PHA", "Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19pandemic response; and the healthcare supply chain.", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-19T10:19:17.687000-04:00"], [2688893, "2f4f19d3-0618-4c28-b306-fbaa5d725cc5", "Q3", "BUCHANAN INGERSOLL & ROONEY PC", 55291, "GENERIC ANIMAL DRUG ALLIANCE", 2021, "third_quarter", "PHA", "Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE", 30000, null, 0, 0, "2021-10-19T10:19:18.140000-04:00"], [2689171, "2b552729-dd3b-4d3a-abd4-668d34fc751a", "Q3", "UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION", 39121, "UNITED FOOD & COMMERCIAL WORKERS INTERNATIONAL UNION", 2021, "third_quarter", "PHA", "Met with Senate staff regarding prescription drug reform.", "HOUSE OF REPRESENTATIVES,SENATE", null, 200000, 0, 0, "2021-10-19T10:45:09.630000-04:00"], [2689452, "86af380f-7bc7-4de6-a56a-2ea7b94f9b58", "Q3", "KOUNTOUPES DENHAM CARR & REID, LLC", 320918, "CVS HEALTH", 2021, "third_quarter", "PHA", "General education about the pharmacy benefit manager/pharmacy and insurance industry.  Issues related to drug pricing.  Issues related to the drug supply chain.  Issues related to the implementation of H.R. 133, Consolidated Appropriations Act for Fiscal Year 2021.  Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution.  Issues related to the Fiscal Year 2022 budget reconciliation process focusing on drug pricing.", "HOUSE OF REPRESENTATIVES,SENATE", 60000, null, 0, 0, "2021-10-19T11:17:06.287000-04:00"], [2689453, "0c7986fe-e86d-4773-8b62-20f525a28681", "Q3", "FORBES-TATE", 400976792, "VERDE TECHNOLOGIES", 2021, "third_quarter", "PHA", "Issues related to healthcare, the environment, law enforcement, and the pharmaceutical industry.", "HOUSE OF REPRESENTATIVES,SENATE", 80000, null, 0, 0, "2021-10-19T11:17:06.720000-04:00"], [2689595, "58cfb562-72f6-4181-927e-0a8f892e24da", "Q3", "SUMMIT PUBLIC AFFAIRS", 401105467, "VANDA PHARMACEUTICALS INC.", 2021, "third_quarter", "PHA", "Issues affecting the pharmaceutical industry, including the prescription drug approval process.\n21st Century Cures Act 2.0 (proposed legislation).", "HOUSE OF REPRESENTATIVES,SENATE", 40000, null, 0, 0, "2021-10-19T11:31:44.320000-04:00"]], "truncated": false, "filtered_table_rows_count": 280, "expanded_columns": [], "expandable_columns": [[{"column": "filing_uuid", "other_table": "lobbying_filings_raw", "other_column": "filing_uuid"}, "registrant_name"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, filing_uuid, filing_type, registrant_name, registrant_id, client_name, filing_year, filing_period, issue_code, specific_issues, government_entities, income_amount, expense_amount, is_no_activity, is_termination, received_date from lobbying_activities where \"filing_period\" = :p0 and \"filing_year\" = :p1 and \"issue_code\" = :p2 order by filing_year desc limit 101", "params": {"p0": "third_quarter", "p1": "2021", "p2": "PHA"}}, "facet_results": {"issue_code": {"name": "issue_code", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": "PHA", "label": "PHA", "count": 280, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021", "selected": true}], "truncated": false}, "filing_year": {"name": "filing_year", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": 2021, "label": 2021, "count": 280, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&issue_code=PHA", "selected": true}], "truncated": false}, "filing_period": {"name": "filing_period", "type": "column", "hideable": false, "toggle_url": "/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA", "results": [{"value": "third_quarter", "label": "third_quarter", "count": 280, "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_year=2021&issue_code=PHA", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "filing_type", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA&_facet=filing_type"}, {"name": "income_amount", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA&_facet=income_amount"}, {"name": "is_termination", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA&_facet=is_termination"}, {"name": "received_date", "type": "date", "toggle_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA&_facet_date=received_date"}], "next": "2021,2689595", "next_url": "https://www.pawtectors.org/lobbying/lobbying_activities.json?filing_period=third_quarter&filing_year=2021&issue_code=PHA&_next=2021%2C2689595&_sort_desc=filing_year", "private": false, "allow_execute_sql": true, "query_ms": 2210.538802901283, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}